Study · Case report or series · n = 4 · 2013

1 result

Evaluation of the effects of exenatide administration in patients with type 2 diabetes with worsened glycemic control caused by glucocorticoid therapy.

Matsuo K, Nambu T, Matsuda Y, Kanai Y, Yonemitsu S, Muro S, Oki S

Internal medicine (Tokyo, Japan)1 Jan 2013Cited by 24 (Europe PMC)

PMID23291680DOI10.2169/internalmedicine.52.8622PepBankPUB-23291680

Source link PubMedAsk about this study

Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

01HumanCase report or seriesEfficacy outcome
In four patients with type 2 diabetes and glucocorticoid-related worsening glycemic control, exenatide treatment was reported as successful.
In plain wordsIn four patients with diabetes and steroid-related glucose worsening, exenatide treatment was reported as successful.
Peptide
Exenatide (exendin-4)
Outcome
Direction not reportedGlycemic control
Study
n = 4
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
We herein report four cases of patients with type 2 diabetes with worsened glycemic control due to glucocorticoids who were successfully treated with exenatide administration.
Report a problemFND-2329168001

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.